SD 101 - Dynavax

Drug Profile

SD 101 - Dynavax

Alternative Names: CpG Class C Immunostimulatory Sequence (ISS) - SD-101 - Dynavax; SD-101 - Dynavax

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Dynavax Technologies
  • Developer Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma; Follicular lymphoma; Malignant melanoma
  • Phase I Haematological malignancies; Lymphoma
  • No development reported Hepatitis C

Most Recent Events

  • 02 Jun 2017 Updated efficacy, adverse events and pharmacodynamics data from a phase Ib/II trial in Malignant melanoma presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 06 Mar 2017 Updated interim adverse events, pharmacodynamics and efficacy data from a phase Ib/II trial in Malignant melanoma released by Dynavax
  • 26 Jan 2017 Dynavax completes a phase I/II trial of SD 101 in combination with ipilimumab and local radiation in B-cell lymphoma in USA (NCT02254772)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top